POSTTRANSPLANT HEMOLYTIC UREMIC SYNDROME IN ADULT RETRANSPLANTED KIDNEY GRAFT RECIPIENTS: ADVANTAGE OF FK506 THERAPY?

Abstract

Our results demonstrate that three of seven renal allograft recipients benefited from FK506 therapy for prevention or resolution of pHUS. Treatment or prophylaxis with FK506 can be considered advantageous in some patients with de novo pHUS, but FK506 fails to prevent recurrent pHUS in patients with primary HUS.